Allogene Therapeutics, Inc. has grown revenue 302% a year over three years and −29% a year over five. Revenue growth, 3-year annual rate: +302% (Biotechnology median +17%). Revenue growth, 5-year rate: −29%, growth has picked up over the last three years. Years of annual history on file: 8, FY2018 to FY2025, as filed.

ALLOAllogene Therapeutics, Inc.

Healthcare

$1.40+3.7% 1Y

$1.40

$1.0552 weeks$3.06

Is it growing?

Good

Operating margin widening (+342194.8 points). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

Margin direction+342194.8 points operatingSEC EDGAR · Jun 30, 2026

Trailing-twelve-month operating margin, -4811.2% now against -347006.0% a year earlier.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ALLO growing?

Allogene Therapeutics, Inc. has grown revenue 302% a year over three years and −29% a year over five.

+302%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −29%
Revenue growth, 5-year rate · +302% over three · growth has picked up over the last three years
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed

Details›